Literature DB >> 35969315

HYPOTHESIS: Do LRIG Proteins Regulate Stem Cell Quiescence by Promoting BMP Signaling?

Carl Herdenberg1, Håkan Hedman2.   

Abstract

Leucine-rich repeats and immunoglobulin-like domains (LRIG) proteins are evolutionarily conserved integral membrane proteins. Mammalian LRIG1 regulates stem cell quiescence in various tissue compartments, including compartments in the epidermis, oral mucosa, intestines, neural system, and incisors. The planarian LRIG1 homolog regulates the quiescence of multipotent neoblasts. The mechanism through which LRIG proteins regulate stem cell quiescence has not been well documented, although it is generally assumed that LRIG1 regulates the epidermal growth factor receptor (EGFR) or other receptor tyrosine kinases. However, Lrig-null (Lrig1-/-;Lrig2-/-; and Lrig3-/-) mouse embryonic fibroblasts (MEFs) have been recently found to exhibit apparently normal receptor tyrosine kinase functions. Moreover, bone morphogenetic protein (BMP) signaling has been shown to depend on LRIG1 and LRIG3 expression. BMPs are well-known regulators of stem cell quiescence. Here, we hypothesize that LRIG1 might regulate stem cell quiescence by promoting BMP signaling. HYPOTHESIS: Based on recent findings, it is hypothesized that LRIG1 regulates stem cell quiescence in mammalian tissues as well as in planarian neoblasts by promoting BMP signaling.
© 2022. The Author(s).

Entities:  

Keywords:  BMP; EGF; LRIG1; Quiescence; Stem cell

Year:  2022        PMID: 35969315     DOI: 10.1007/s12015-022-10442-9

Source DB:  PubMed          Journal:  Stem Cell Rev Rep        ISSN: 2629-3277            Impact factor:   6.692


  58 in total

1.  cDNA cloning of a novel membrane glycoprotein that is expressed specifically in glial cells in the mouse brain. LIG-1, a protein with leucine-rich repeats and immunoglobulin-like domains.

Authors:  Y Suzuki; N Sato; M Tohyama; A Wanaka; T Takagi
Journal:  J Biol Chem       Date:  1996-09-13       Impact factor: 5.157

2.  Cloning, characterization, and expression of human LIG1.

Authors:  J Nilsson; C Vallbo; D Guo; I Golovleva; B Hallberg; R Henriksson; H Hedman
Journal:  Biochem Biophys Res Commun       Date:  2001-06-29       Impact factor: 3.575

Review 3.  Harnessing LRIG1-mediated inhibition of receptor tyrosine kinases for cancer therapy.

Authors:  Virginie Neirinckx; Hakan Hedman; Simone P Niclou
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2017-03-01       Impact factor: 10.680

Review 4.  LRIG inhibitors of growth factor signalling - double-edged swords in human cancer?

Authors:  Håkan Hedman; Roger Henriksson
Journal:  Eur J Cancer       Date:  2007-01-18       Impact factor: 9.162

5.  LRIG1 extracellular domain: structure and function analysis.

Authors:  Yibin Xu; Priscilla Soo; Francesca Walker; Hui Hua Zhang; Nicholas Redpath; Chin Wee Tan; Nicos A Nicola; Timothy E Adams; Thomas P Garrett; Jian-Guo Zhang; Antony W Burgess
Journal:  J Mol Biol       Date:  2015-03-09       Impact factor: 5.469

6.  Characterization and tissue-specific expression of human LRIG2.

Authors:  Camilla Holmlund; Jonas Nilsson; Dongsheng Guo; Anna Starefeldt; Irina Golovleva; Roger Henriksson; Håkan Hedman
Journal:  Gene       Date:  2004-05-12       Impact factor: 3.688

7.  The LRIG gene family has three vertebrate paralogs widely expressed in human and mouse tissues and a homolog in Ascidiacea.

Authors:  Dongsheng Guo; Camilla Holmlund; Roger Henriksson; Håkan Hedman
Journal:  Genomics       Date:  2004-07       Impact factor: 5.736

Review 8.  LRIG1, a regulator of stem cell quiescence and a pleiotropic feedback tumor suppressor.

Authors:  Yibing Ji; Rahul Kumar; Abhiram Gokhale; Hseu-Ping Chao; Kiera Rycaj; Xin Chen; Qiuhui Li; Dean G Tang
Journal:  Semin Cancer Biol       Date:  2021-01-18       Impact factor: 17.012

9.  LRIG proteins regulate lipid metabolism via BMP signaling and affect the risk of type 2 diabetes.

Authors:  Carl Herdenberg; Pascal M Mutie; Ola Billing; Ahmad Abdullah; Rona J Strawbridge; Ingrid Dahlman; Simon Tuck; Camilla Holmlund; Peter Arner; Roger Henriksson; Paul W Franks; Håkan Hedman
Journal:  Commun Biol       Date:  2021-01-19

Review 10.  LRIG1 is a triple threat: ERBB negative regulator, intestinal stem cell marker and tumour suppressor.

Authors:  Y Wang; E J Poulin; R J Coffey
Journal:  Br J Cancer       Date:  2013-04-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.